Developing drugs to fight COVID-19 by targeting a key viral enzyme
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease
This study is working on new antiviral medicines that could help stop the COVID-19 virus from making you sick by blocking a key part of the virus, and it aims to provide better treatment options for anyone dealing with COVID-19 or similar infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11177104 on NIH RePORTER |
What this research studies
This research focuses on creating antiviral drugs that target the 3C-like protease (3CLpro) of the SARS-CoV-2 virus, which is responsible for COVID-19. By inhibiting this enzyme, the research aims to prevent the virus from replicating and causing severe illness. The approach involves designing small-molecule inhibitors that can be used both as preventive measures and therapeutic treatments for COVID-19 and other coronavirus infections. Patients may benefit from new treatment options that could reduce the severity of COVID-19 symptoms and complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of severe COVID-19, including those with underlying health conditions or those who have tested positive for the virus.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective antiviral medications that significantly improve outcomes for patients with COVID-19.
How similar studies have performed: Previous research has shown promise in targeting viral enzymes for antiviral drug development, indicating potential success for this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Schinazi, Raymond Felix — Emory University
- Study coordinator: Schinazi, Raymond Felix
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.